A study of CD117 expression in dermatofibrosarcoma protuberans and cellular dermatofibroma

Abstract

Our study on a relatively large number of cases confirms the negativity of DFSP and CDF for CD117. Therefore, if adjuvant therapy is attempted with drugs such as STI571 (Imatinib), the eligibility of patients should not be based on immunohistochemical assessment of CD117 expression.